Table 1.
Patient characteristics
| Pre-IFX patients | Non-IFX patients | P value | |
|---|---|---|---|
| Number of patients | 908 | 6,191 | |
| Sex, n (%) | |||
| Men | 186 (20.5) | 1,160 (18.7) | ns |
| Women | 722 (79.5) | 5,031 (81.3) | ns |
| Mean age ± SD, years | 54.2 ± 13.2 | 58.9 ± 12.7 | <0.001 |
| Mean body weight ± SD, kg | 54.2 ± 9.8 | 53.1 ± 10.2 | 0.018 |
| Presence of any past history, n (%) | 224 (24.7) | 1,855 (30.0) | <0.001 |
| Comorbidities present, n (%) | 472 (52.0) | 3,661 (59.1) | <0.001 |
| Mean duration of RA, years | 9.0 | 9.9 | <0.001 |
| Previous steroid use, n (%) | 824 (90.8) | 5,248 (84.8) | <0.001 |
| Mean DAS28 ± SD* | 6.1 ± 1.2 | 6.0 ± 1.2 | ns |
| Concomitant use of DMARDs, % | 87.1 | 68.7 | <0.001 |
| Concomitant use of MTX, n (%) | 80.9 | 48.6 | <0.001 |
DAS28 Disease Activity Score including 28-joint count; DMARDs disease-modifying antirheumatic drugs; IFX infliximab; MTX methotrexate; ns not significant; RA rheumatoid arthritis
* n = 501 for patients switching from IFX; n = 4,142 for patients not switching from IFX